Anifrolumab

Anifrolumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Interferon α/β receptor
Clinical data
Trade names	Saphnelo
Other names	MEDI-546, anifrolumab-fnia
AHFS/Drugs.com	Monograph
License data	US DailyMed: Anifrolumab;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous
Drug class	type I interferon receptor antagonist (IFN)
ATC code	L04AG11 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1326232-46-5;
DrugBank	DB11976;
ChemSpider	none;
UNII	38RL9AE51Q;
KEGG	D11082;
Chemical and physical data
Formula	C6444H9964N1712O2018S44
Molar mass	145119.20 g·mol−1

Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.

Anifrolumab was approved for medical use in the United States in July 2021, and in the European Union in February 2022. The U.S. Food and Drug Administration considers it to be a first-in-class medication.